{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009856","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.289559+00:00","generated_at":"2026-06-17T08:05:03.005201+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ensysce reports FY2022 net loss $24.2M, cash $3.1M; $3M equity raise; clinical milestones achieved","bullets":["Q4 net loss $5.5M ($10.0M prior year); FY2022 net loss $24.2M ($29.1M prior year).","Cash at Dec 31, 2022 $3.1M, down from $12.3M year ago; raised $3M post-year-end at $0.84/share.","R&D expenses Q4 $6.4M (up from $2.2M prior year); FY $19.8M (up from $4.7M prior year) due to clinical trials.","Clinical progress: PF614 oral HAP study database locked Feb 2023; FDA guidance supports acute pain indication; PF614-MPAR Phase 1 fully enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009856","json":"https://secwatch.observer/filing/0001493152-23-009856.json","markdown":"https://secwatch.observer/filing/0001493152-23-009856.md","text":"https://secwatch.observer/filing/0001493152-23-009856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/0001493152-23-009856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:05:03.005201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5426991a14e2dfeb44cddfe22580e8b5b846e1a9","claim":"Ensysce Biosciences, Inc. reported the fourth quarter of 2022 results: net income $5.5 million.","evidence_excerpt":"Net loss for the fourth quarter of 2022 was $5.5 million compared to $10.0 million for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/0001493152-23-009856-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Net income","value":"$5.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"787877df8b930a92daccb9c94120411d1e12f4cf","claim":"Ensysce Biosciences, Inc. reported the full year of 2022 results: net income $24.2 million.","evidence_excerpt":"For the full year of 2022, net loss was $24.2 million compared to $29.1 million for the full year of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/0001493152-23-009856-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year of 2022"},{"label":"Net income","value":"$24.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}